Autologous IL-7/CCL19-expressing Anti-GM2 CAR T Cells NIB-101 - CISMeF
Autologous IL-7/CCL19-expressing Anti-GM2 CAR T Cells NIB-101NCIt concept
Preferred Label : Autologous IL-7/CCL19-expressing Anti-GM2 CAR T Cells NIB-101;
NCIt synonyms : Autologous Anti-GM2 PRIME CAR T Cells NIB-101; Autologous Anti-GM2 CAR T-cells NIB-101;
NCIt definition : A preparation of autologous T-lymphocytes that have been genetically modified to express
a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) ganglioside
GM2 (GM2) and producing the immune regulators interleukin-7 (IL-7) and C-C motif chemokine
19 (CCL19) using PRIME (proliferation-inducing and migration-enhancing) technology,
with potential immunostimulating and antineoplastic activities. Upon administration,
autologous IL-7/CCL19-expressing anti-GM2 CAR T-cells NIB-101 target and bind to GM2-expressing
tumor cells, thereby inducing selective toxicity in GM2-expressing tumor cells. In
addition, as IL-7 promotes the proliferation and survival of T-cells and CCL19 enhances
the migration of host T-cells and dendritic cells (DCs), the production of IL-7 and
CCL19 by NIB-101 allows for enhanced trafficking and accumulation of the PRIME CAR-T
cells and other endogenous immune cells, including T-cells and DCs in tumor tissues.
This further activates the host immune system to induce anti-tumor immune responses
to various cancer antigens and against tumor cells lacking the CAR target antigen.
GM2, a type of glycosphingolipid, is overexpressed on the surface of many cancer cells,
such as multiple myeloma (MM) cells and neuroblastoma cells.;